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Methods
Study population. The ethics committee of the University of Leuven approved the Flemish Study on Environment, Genes and Health Outcomes (FLEMENGHO). As described in detail in previous publications, 9 from August 1985 until December 2005, we recruited a random sample of families from a geographically defined area in northern Belgium. From May 2005 until June 2009, we reinvited 1,184 former participants for a follow-up examination including echocardiography. Of those, 18 had moved out of the study area, 26 had died, 27 were severely ill, and 82 did not respond. Of the remaining 1,031 former participants, 802 (77.8%) renewed their consent in writing and took part in the study.
We excluded participants from analysis, because they had a history of myocardial infarction or coronary revascularization (n = 26), valvular heart disease (n = 33), cardiac arrhythmias or pacemaker implantation (n = 12), cardiomyopathy (n = 1), or congenital heart disease (n = 1); because their echocardiogram was of insufficient quality (n = 11); or because they had not been genotyped for AGTR1 A1166C (n = 10). Thus, our analysis encompassed 708 participants.
Echocardiography. The participants refrained from heavy exercise, smoking or drinking alcohol for at least 3 h before echocardiography. One experienced observer (T.K.) performed all echocardiograms 10 according to the recommendations of the American Society of Echocardiography, 11 using a Vivid 7 Pro (GE Vingmed, Horten, Norway) interfaced with a 2.5-3.5 MHz phased-array probe. The observer obtained M-mode echocardiograms of the LV from the parasternal long-axis view guided by two-dimensional image. All recordings were digitally stored for offline analysis by the EchoPac software package, version 4.0.4 (GE Vingmed).
We measured LV internal diameter (LVID), interventricular septum (IVS) and posterior wall thickness (PWT) at enddiastole from the M-mode image. In case the orientation of the M-mode ultrasound beam was suboptimal, we performed linear measurements on correctly oriented two-dimensional images. All measurements were made by the leading-edge method 12 and averaged over three cardiac cycles. Mean wall thickness (MWT) was the sum of IVS and PWT divided by two. We computed LV mass in grams from a validated formula 13 as 0.8 × (1.04 ((LVID + IVS + PWT) 3 -LVID 3 )) + 0.6. LV mass index was LV mass divided by body surface area, calculated as body weight 0.425 (in kg) × body height 0.725 (in cm) × 0.007184. The intraobserver intrasession variability of LV mass was 4.3%. 10 Other measurements. Body mass index was weight in kilograms divided by the square of height in meters. After the participants had rested for 5 min in the sitting position, the trained nurses obtained five consecutive blood pressure readings (phase V diastolic) to the nearest 2 mm Hg, using a standard mercury sphygmomanometer. Standard cuffs had a 12 × 24 cm inflatable portion, but if upper arm girth exceeded 31 cm, larger cuffs with 15 × 35 cm bladders were used. For analysis, the five blood pressure readings were averaged. Hypertension was a blood pressure of at least 140 mm Hg systolic or 90 mm Hg diastolic, or use of antihypertensive medications. The nurses administered a standardized questionnaire to collect information on the participants′ medical history, smoking and drinking habits, and intake of medications. From the type and quantity of the alcoholic beverages used, we computed alcohol consumption in g/day. Regular drinking was a consumption of at least 5 g/day. The participants collected a 24-h urine sample in a wide-neck plastic container. Sodium and potassium in urine were determined by flame photometry, creatinine by an automated enzymatic method, and aldosterone concentration by radioimmunoassay.
Determination of genotypes. Genomic DNA was extracted from white blood cells, using standard kits (Qiagen, Hilden, Germany). DNA fragments that contained the A1166C polymorphism were amplified by PCR with the forward 5´-GTAAGCTCATCCACCAAGAAGC-3´and reverse 5´-GCAAGTGTAGCAGCAGTTGC-3´ primers. The PCR products were digested overnight by the addition of 10U of DdeI restriction enzyme. In the presence of the 1166C allele, the PCR product (519 bp) was cut into two fragments of 385 and 134 bp in length and visualized on ethidium bromide-stained 2% agarose gels. As a standard procedure, we checked heterozygous and homozygous genotypes by appropriate controls in each plate (genotype controls were directly sequenced).
Statistical methods. For database management and statistical analyses, we used SAS software, version 9.1.3 (SAS Institute, Cary, NC). We normalized the distributions of plasma renin activity and the urinary aldosterone excretion by a logarithmic transformation. We compared means and proportions, using analysis of variance with Dunnett's adjustment of the significance level and the χ 2 statistic, respectively. We tested the Hardy-Weinberg equilibrium, using the SAS procedure PROC ALLELE. We included in our models covariables with known physiologic relevance 8, 14 for LV structure. We additionally searched for possible covariables, using stepwise multiple regression with P values for independent variables to enter and to stay in the models set at 0.15.
We applied a generalization of the standard linear model, as implemented in the PROC MIXED procedure of the SAS package, to investigate associations between the echocardiographic measurements and explanatory variables, while accounting for relatedness among study participants and adjusting for covariables. We considered codominant (CC vs. AC vs. AA) and recessive (CC vs. AC + AA) inheritance models. With currently available sample size, our study had 80% power to detect a difference of 7.7 g/m 2 [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . In regular drinkers, the median alcohol consumption was 11 g/day (interquartile range: [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] .
genotype frequencies
The genotype frequencies were 348 (49.1%), 303 (42.8%), and 57 (8.1%) for AA, AC, and CC, respectively, and complied with Hardy-Weinberg equilibrium (P = 0.43). The frequencies of the A and C allele were 70.5% and 29.5%. Table 1 lists the characteristics of participants by A1166C genotypes. Anthropometric characteristics, the prevalence of smoking and drinking, and the biochemical measurements on blood and 24-h urine samples, did not differ between genotypes (P ≥ 0.09). Furthermore, all characteristics listed in Table 1 were similar in CC homozygotes and A-allele carriers, with the exception of 24-h urinary aldosterone, which was higher in A-allele carriers (geometric mean, 22.6 vs. 19.0 nmol/day; P = 0.047). Table 2 summarizes the echocardiographic measurements by genotype. Analysis of variance showed significant differences across genotypes in IVS and MWT. CC homozygotes had increased IVS compared to AC heterozygotes (+0.73 mm; simultaneous 95% confidence interval, +0.15 to +1.29 mm) and AA homozygotes (+0.67 mm; simultaneous 95% confidence interval, +0.10 to +1.22 mm). Along similar lines, CC homozygotes also had increased MWT compared with AC heterozygotes (+0.56 mm, simultaneous 95% confidence interval, +0.07 to +1.06 mm), and AA homozygotes (+0.53 mm, simultaneous 95% CI, +0.04 to +1.02 mm). The difference in MWT between the AC and AA genotypes was not statistically significant (P = 0.95). Using an unadjusted recessive model, CC homozygotes compared to A-allele carriers had increased LV 
unadjusted analyses
Multivariable-adjusted analyses
Multivariable analyses accounted for sex, age, body weight, and height (not applicable to LV mass index), systolic blood pressure, heart rate, smoking and drinking, and antihypertensive treatment. While adjusting for these covariables and accounting for family clusters, there were significant differences across genotypes in LV mass index, MWT, IVS, and PWT ( Table 3 ) produced results that were highly consistent with those in the whole study population. Furthermore, additional adjustment for 24-h urinary sodium and/or aldosterone did not alter our results. Because 24-h urinary aldosterone differed between A-allele carriers and CC homozygotes, we tested the interaction between these variables in relation to LV structure (Figure 1) . For a doubling of urinary aldosterone excretion LV mass index All values are least square means ± s.e., adjusted for sex, age, body weight, and height (not applicable to LV mass index), systolic blood pressure, heart rate, smoking and drinking, and antihypertensive treatment. The analyses also accounted for family clusters. P values are for the differences across genotypes in a codominant model or for difference between CC homozygotes and A-allele carriers in the recessive model. LV, left ventricular. original contributions
AGTR1 and Left Ventricular Mass
increased by 2.21 g/m 2 (P = 0.004) in A-allele carriers, but decreased by 7.62 g/m 2 (P = 0.02) in CC homozygotes (P for interaction, P = 0.001). This was mainly due to opposite trends between CC homozygotes and A-allele carriers in LVID and MWT. Analyses in untreated participants were confirmatory (Figure 1) .
discussion
The key finding of our study was that in multivariable-adjusted analyses, which also accounted for family clusters, CC homozygotes of the AGTR1 A1166C polymorphism had significantly higher LV mass index compared to A-allele carriers. Increased LV wall thickness explained this observation. This association complied with a recessive inheritance model. Sensitivity analyses in untreated participants and additional adjustment for 24-h urinary sodium and aldosterone were confirmatory. The AGTR1 gene maps to 3q24 on the long arm of human chromosome 3. In 1994, Bonnardeaux et al. 15 identified five polymorphisms in the AGTR1 gene in 60 hypertensive patients with a familial susceptibility. In a subsequent case-control study involving white hypertensive (n = 206) and normotensive (n = 298) participants, the 1166C allele showed a significantly higher frequency in the hypertensive patients (0.36 vs. 0.28, P < 0.01). There was no linkage of hypertension with this polymorphism in 267 sib pairs from 138 pedigrees. Bonnardeaux et al. concluded that the AGTR1 A1166C polymorphism might be a common variant of AGTR1 potentially explaining a small part of blood pressure variability. However, subsequent studies were contradictory and did not definitely confirm association of the AGTR1 A1166C polymorphism with hypertension. 4 None of the recent GWAS studies in hypertension picked up a signal with genome-wide significance on the long arm of chromosome 3 near the locus of the AGTR1 gene. 16 Several previous studies investigated the association of LV mass or LV mass index with the AGTR1 A1166C polymorphism in the general population, 17, 18 hypertensive patients, 19, 20 patients selected on the basis of various cardiovascular conditions 21, 22 or in athletes. [23] [24] [25] [26] Most of these studies had a small sample size or predominantly included participants on antihypertensive drugs, which potentially modified the phenotype. Among 212 participants (21 CC homozygotes) randomly recruited from a general population in northern Italy, Castellano et al. 17 did not observe an association of the AGTR1 A1166C polymorphism with LV mass both before and after adjustment for sex, age, height, weight, blood pressure, and smoking. In a family based study 18 conducted in three European populations and involving 815 participants (43 CC homozygotes), we likewise did not find a multivariableadjusted association between LV mass index and the AGTR1 A1166C genotypes.
In a cross-sectional study of 8,592 inhabitants of Groningen (708 CC homozygotes), the prevalence of electrocardiographic LV hypertrophy was 5.0%. 27 There was interaction (P = 0.033) between creatinine clearance and the AGTR1 A1166C genotype in relation to the risk of LV hypertrophy. In participants with the CC genotype, the prevalence of LV hypertrophy increased with more pronounced renal dysfunction, whereas this was not the case in A-allele carriers. In two reports respectively based on 148 and 176 cases and a similar number of controls recruited from a Chinese population, Wu and colleagues 28, 29 reported an association of diastolic heart failure with the AGTR1 A1166C polymorphism. However, in the first report, 28 CC genotype occurred in four cases and none of the controls, while in the second report, 29 the prevalence of minor allele was only 3.2%.
The interpretation of our current findings in the light of the available literature requires consideration of several issues. First, the prevalence of the CC genotype in Caucasians is around 8%, whereas in Asians 28, 29 and African Americans it is below 1%. If the association between LV structure and the AGTR1 A1166C polymorphism follows a recessive model as shown by our current analysis, few other studies included enough CC homozygotes to attain a significant difference with the A-allele carriers. Second, echocardiography is more sensitive than electrocardiography in diagnosis of LV hypertrophy. 30 Current evidence also support that the relation between cardiovascular risk and LV mass is continuous. 31 In contrast to previous study 27 , we did not dichotomize our phenotype. We used LV mass instead of LV hypertrophy in our analyses, and therefore provided full phenotypic information. Third, our study includes a random population sample recruited from a Caucasian population, and has therefore greater external validity than a case-control study in selected patients. Fourth, echocardiographic LV mass is calculated from the end-diastolic diameter and wall thickness. Variability between observers in acquiring and analyzing echocardiographic traits must attenuate phenotype-genotype associations in particular in large-scale studies running over several years. In our study, only one experienced observer performed all ultrasound examinations. Cardiac imaging using magnetic resonance might be an alternative to echocardiography, but is too expensive for implementation in epidemiologic studies.
Martin et al. 32 first demonstrated that microRNA-155 could bind to the 3′-untranslated region of the human AGTR1 mRNA, and could translationally repress the expression of this protein. Further research 4, 5 revealed that the A1166C polymorphism is located within the microRNA-155 target site on human AGTR1 gene. The presence of the 1166C allele impairs the ability of microRNA-155 to bind to its target site. Therefore, human microRNA-155 downregulates the expression of AGTR1 only in the presence of the 1166A, not the 1166C allele. This result was independently reproduced by Nossent et al. 33 very recently. Moreover, the observation that AGTR1 and microRNA-155 are abundantly coexpressed in the same cells, such as vascular smooth muscle cells or human endothelial cells, further supports the plausibility of this mechanism. 5 Recently, Ceolotto et al. 34 investigated the relation between microRNA-155, the A1166C polymorphism and the AGTR1 expression in 64 untreated hypertensive patients. MicroRNA-155 expression was significantly lower in patients with the CC genotype in comparison with the AA and AC genotypes, while the AGTR1 protein expressed in circulating peripheral blood original contributions AGTR1 and Left Ventricular Mass mononuclear cell was 70% higher in the participants with CC genotype. AGTR1 protein expression was also negatively correlated with microRNA-155 expression level (r = -0.34, P < 0.01). Ang II, via AGTR1 receptors, induces vasoconstriction, vascular smooth muscle cell growth and hypertrophy, promotes extracellular matrix formation, and stimulates catecholamine release. In an experiment using animal models, overexpression of AGTR1 in cardiomyocytes induces cardiac hypertrophy and remodeling. 35 Therefore, enhanced expression of AGTR1 in CC homozygotes might favor the development of LV hypertrophy and increase ventricular wall thickness.
In sensitivity analyses, we found an interaction between 24-h urinary aldosterone and A1166C polymorphism in relation to LV mass index. The 24-h urinary aldosterone excretion was significantly lower in CC homozygotes compared with A-allele carriers. In keeping with our previous report, 36 LV mass index increased with higher 24-h aldosterone excretion in A-allele carriers. In CC homozygotes, LV mass decreased with higher aldosterone excretion. We can only speculate the possible mechanism for this interaction. Ang II stimulates the synthesis of aldosterone by triggering the calcium messenger system, but this signaling mechanism might be subject to a negative feedback control. For instance, Ang II exerts a profound inhibition of steroidogenesis in K + -stimulated rat adrenal glomerulosa cells. 37 We speculate that the lower aldosterone excretion in CC homozygotes might be due to a negative feedback because of the long-term enhanced expression of the AGTR1 in the adrenal zona glomerulosa.
The present study has to be interpreted within the context of its limitations. First, we did not sequence the entire human AGTR1 gene. Instead, we selected this A1166C polymorphism based on evidence from experimental and human studies. Second, we did not measure the expression of AGTR1 protein in circulating blood cells. However, the aforementioned study by Ceolotto et al. 34 demonstrated higher expression of AGTR1 in circulating peripheral blood monocytes harvested from CC homozygotes compared with those of A-allele carriers. Third, our sample size was relatively small, so our current findings need replication in other population studies. Moreover, the current literature does not offer a clear explanation why 24-h urinary aldosterone excretion was lower in CC homozygotes than A-allele carriers. This finding needs further clarification by other studies.
In conclusion, LV mass index is associated with the AGTR1 A1166C polymorphism. Further research should clarify to what extent this association might be mediated via different expression of AGTR1 as modulated by microRNA-155. Confirmation of this concept might identify microRNA-155 as a possible target for prevention and treatment of LV hypertrophy.
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